Acorda Therapeutics, Inc. today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda s Chief of Business Operations, will assume responsibility for the company s Chelsea, MA manufacturi
Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative in 2017, ActiGraph's Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the...
Actinium Pharmaceuticals, Inc., today announced that it will conduct a conference call on Wednesday, August 15, 2018 at 9:00 AM ET to provide an update on the Pivotal Phase 3 SIERRA Trial of Iomab-B. Date: Wednesday, August 15, 2018 Time: 9:00 AM ET Registration Link: https://onecast.thinkpragmatic.com/ses/HKwlrC68IHB-UiNbwrpb4w~~ Toll-Free Dial-
-Adherium, a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie solution in the U.S., following its recent Food and Drug Administration 510 over-the-counter clearance to enable sales direct to consumers. Adherium believes health technology should be simple to use
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. We had a busy and productive second quarter at Aerpio, commented Stephen Hoffman, M.D. Second, we completed an
Aevi Genomic Medicine, Inc. today announced that it has completed enrollment in Part A of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder, to confirm response to AEVI-001 in these patients. "We are pleased that we hav
This is a significant victory for Alnylam, and for biotech in general, which has been struggling for more than a decade to transform RNAi technology into an approval medicine. Alnylam has beaten off competition in the US from RNAi company Ionis, which is developing a rival therapy for hATTR, Tegsedi. But Alnylam is ahead in the bigger US market, wh
Amicus Therapeutics Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease. Galafold was approved using the Accelerated Approval pathway, which allows the US Food and Drug Administration to approve drugs for serious conditions where there is an unmet medical need if a treatment drug is shown
Amicus Therapeutics first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy. The oral drug is an alternative to the infused enzyme replacement therapy that is current standard of care Sanofi/ Genzymes Fabarazyme. Already approved in Europe,
The battle between Vertex Pharmaceuticals and U.K. health officials over cystic fibrosis drug pricing has reached an impasse after NHS Englands final offer in July. In a statement, Vertex director of external communications Heather Nichols said the company supports the need for robust and fair medicines appraisal in England. Vertex and U.K. health.
This management's discussion and analysis of the financial condition and results of operations of the Company should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes for the three and six months ended June 30, 2018 and 2017, which have been prepared in accordance with United States general
Non-profit research organisation Population Council has secured the US Food and Drug Administration approval for a new contraceptive vaginal ring called Annovera. Population Council president Julia Bunting said: Nearly half of all pregnancies in the US are unintended, which can increase health risks for mom and baby. During the Phase III programme,
VANCOUVER- Aquinox Pharmaceuticals, Inc., a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, 2018. As a result, we've halted all development activities for rosipt
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that the Company`s lipid nanoparticle licensee, Alnylam Pharmaceuticals, Inc., announced that their new drug application for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration for the treatment o
-Arch Biopartners, Inc., a portfolio-based biotechnology company, today announced it has engaged Dalton Pharma Services to perform the good manufacturing practice campaign for Metablok,, the Company's drug candidate for preventing acute kidney injury. said Peter Pekos, CEO and President, Dalton Pharma Services. " We are on schedule for producing a
Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties including, but not limited to the factors set forth under the heading "Forward Looking Statements" and "Item 1 A. Risk Factors" under Part I of this Annual Report on Form 10- K, and in other reports we file with the SEC. Ther
Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs. "We were thrilled to launch BRAFTOVI?+ MEKTOVI for patients with BRAF- mutant melanoma in the U.S. after receiving FDA approval for the combi
Arrayit Corporation, a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens.
PASADENA- Arrowhead Pharmaceuticals Inc. today announced financial results for its fiscal 2018 third quarter ended June 30, 2018. Made presentations at the EASL International Liver Congress, including: Preclinical data on ARO-AAT, the second generation candidate for the treatment of alpha-1 antitrypsin deficiency liver disease, Preclinical data on.
Avenue Therapeutics, Inc., a specialty pharmaceutical company focused on the development and commercialization of intravenous tramadol, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2018. Cash Position: As of June 30, 2018, Avenue s cash, cash equivalents and short-term investments total
AVEO Oncology today announced that the China National Drug Administration has accepted CANbridge Life Sciences Investigational New Drug Application for a Phase Ib/III clinical trial of CAN017, AVEO s clinical-stage ErbB3 inhibitory antibody candidate, in esophageal squamous cell cancer. Under the terms of a March 2016 agreement, the acceptanc
On August 14, 2018, AVEO Pharmaceuticals, Inc. issued a press release announcing that the China National Drug Administration has accepted an investigational new drug application of CANbridge Life Sciences for a Phase 1 b/III clinical trial of CAN017 in esophageal squamous cell cancer. CAN017, which the Company refers to as AV-203, is the Company's.
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the quarter ended June 30, 2018, and provided a review of recent accomplishments and anticipated...
NESS ZIONA, Israel, Aug. 14, 2018/ PRNewswire/- BiondVax Pharmaceuticals Ltd., developer of M 001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a ?6 million disbursement from the European Investment Bank. These funds are the second tranche of the previously announced ?20 million co-financing agre